跳至主要内容
临床试验/TCTR20190515002
TCTR20190515002尚未招募未知

Comparison between non-switching and early-switching therapy to aflibercept in diabetic macula edema with suboptimal response to prior treatment with bevacizumab.

/A0 个研究点目标入组 110 人开始时间: 2019年5月15日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
110

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 100 Years(—)
性别
All

入选标准

  • - Patient with center-involved DME with suboptimal response to 3 monthly initial bevacizumab
  • injections (defined as persistent DME in central fovea, intraretinal cystoid space or subretinal
  • fluid persisted, with central subfield thickness ≥305 microns in women and ≥320 microns in
  • men by Heidelberg Spectralis OCT after 3 consecutive injection of bevacizumab)
  • - Age > 18 years old
  • - Visual acuity 6/7.5 †6/240 (20/25 †20/800)
  • - No history of prior intravitreal injections or laser to treat macular edema

排除标准

  • - Patients with other disorders affecting macular thickness such as retinal vein occlusion,
  • vitreomacular traction, epiretinal membrane, macular hole, choroidal neovascularization and
  • medication known to cause macular edema
  • - Patients with active proliferative diabetic retinopathy and neovascular glaucoma
  • - Patients with ocular media opacity that preclude OCT imaging
  • - Patients who cannot comply to the 3 monthly follow-up visits
  • - Patients with recent onset of thromboembolic events such as stroke and myocardial infarction
  • within 6 months
  • - Pregnant women

研究者

发起方
/A

相似试验